1. Oil composition comprising 20-10

1. Oil composition comprising 20-100 % by weight of wax esters, preferably 40-85% by weight of wax esters, wherein said wax esters consist of monoesters of predominantly mono- or polyunsaturated C16 to C22 fatty acids and predominantly monounsaturated C16 to C22 fatty alcohols for use as a medicament for the prevention or treatment of abdominal obesity and obesity related disease.
2. Composition according to claim 1 wherein 70% or more of the monounsaturated fatty alcohols of the wax esters are C 16: 1, C20: l and C22:l.
3. Composition according to claim 1 wherein 70% or more of the fatty alcohols of the wax esters are monounsaturated, and wherein 50% or more of the fatty acids of the wax ester are either mono- or polyunsaturated n-3 fatty acids.
4. Composition according to claim 1 wherein said obesity related disease is type 2 diabetes or cardiovascular disease.
5. Composition according to any one of claims 1 to 4 wherein the composition comprises 5-20 % by weight of stearidonic acid (SDA).
6. Composition according to any one of claims 1 to 5 wherein the composition comprises 3-20 % by weight of eicosapentaenoic acid (EPA) and 2-15 % by weight of docosahexaenoic acid (DHA).
7. Composition according to any one of claims 1 to 6 wherein the composition comprises fatty alcohols and SDA, DHA and EPA as monoesters.
8. Composition according to any one of claims 1 to 7 wherein the composition contains 500-4000 ppm of astaxanthin.
9. Composition according to any one of claims 1 to 8 wherein said composition is isolated from a copepod.
10. Composition according to claim 9 wherein said copepod is of the genus Calanus.
11. Composition according to claim 10 wherein said copepod is of the species Calanus finmarchicus.
12. Dietary supplement formulation comprising a composition according to any one of claims 1-11.
13. Functional food or feed formulation comprising a composition according to any one of claims 1-11.
14. A pharmaceutical formulation comprising a composition according to any one of claims 1-11.
15. A formulation according to claims 12 or 14 provided in capsules, tablets, emulsions or tonics.
16. A formulation according to claim 15 comprising one or more pharmaceutically acceptable additives selected from the group consisting of adjuvants, stabilizers, antioxidants, emulsifϊers, surfactants and carriers.
17. Use of a composition according to claims 1-11 for the manufacture of medicaments for the prevention or treatment of abdominal obesity.
18. Use of a composition according to claims 1-11 for the manufacture of medicaments for the prevention or treatment of an obesity related disease.
19. Use according to claim 18 wherein said obesity related disease is type 2 diabetes or cardiovascular disease.
20. A method for the prevention or treatment of abdominal obesity is provided wherein a daily amount of 0.5 to 5 g of an oil composition according to claims 1-8 is administered to a human subject in need of such treatment.
21. A method according to claim 18 wherein said obesity related disease is type 2 diabetes or cardiovascular disease.

ผลลัพธ์ (อังกฤษ) 2:

1. Oil composition comprising 20-100% by weight of wax esters, preferably 40-85% by weight of wax esters, wherein said wax esters consist of monoesters of predominantly mono- or polyunsaturated C16 to C22 fatty acids and predominantly monounsaturated C16 to C22. fatty alcohols for Use As a medicament for The Prevention or Treatment of Obesity and Obesity Related abdominal disease.
2. Composition according to claim 1 wherein 70% or more of The monounsaturated fatty alcohols of The Wax esters are C 16: 1, C20: C22 and L: L.
3. Composition according to claim 1 wherein 70% or more of The fatty alcohols of The Wax esters are monounsaturated, and wherein 50% or more of The fatty acids of The Wax ester are either mono or polyunsaturated n-3 fatty acids.
4. Composition according to claim 1 wherein said disease is type 2 Diabetes or Obesity Related Cardiovascular disease.
5. One composition according to any of Claims 1 to 4 wherein The composition comprises 5-20% by Weight of Stearidonic acid (SDA).
6. One composition according to any of Claims 1 to 5 wherein The composition comprises 3-20% by Weight of eicosapentaenoic acid (EPA) and docosahexaenoic acid 2-15% by Weight of (DHA).
7. One composition according to any of Claims 1 to 6 wherein The composition comprises fatty alcohols and SDA, DHA and EPA As Monoesters.
8. One composition according to any of Claims 1 to 7 wherein 500-4000 PPM Contains The composition of astaxanthin.
9. One composition according to any of Claims 1 to 8 wherein said composition is isolated from a copepod.
10. Composition according to claim 9 wherein said The genus Calanus copepod is of.
11. Composition according to claim 10 wherein said copepod Calanus finmarchicus is of The Species.
12. Supplement dietary formulation comprising a composition according to any of Claims 1-11 One.
13. Food or Feed functional formulation comprising a composition according to any of Claims 1-11 One.
14. A Pharmaceutical formulation comprising a composition according to any of Claims 1-11 One.
15. A formulation according to Claims 12 or 14 Provided in capsules, tablets, emulsions or tonics.
16. A formulation according to claim 15 comprising One or more pharmaceutically Acceptable Additives Selected from The Group consisting of adjuvants, stabilizers, antioxidants, Emulsifϊers, Surfactants and Carriers.
17. Use of a composition according to Claims 1-11 for The Manufacture of medicaments for The Prevention or Treatment of abdominal Obesity.
18. Use of a composition according to Claims 1-11 for The Manufacture of medicaments for The Prevention or Treatment of an Obesity Related disease.
19. Use according to claim 18 wherein said disease is type 2 Diabetes or Obesity Related Cardiovascular disease.
20. A Method for The Prevention or Treatment of abdominal Obesity is Provided wherein a Daily amount of 0.5 to 5 G of an Oil composition according to Claims 1-8 is Administered to a Human subject in Need of Such Treatment.
21. A method according to claim 18 wherein said obesity related disease is type 2 diabetes or cardiovascular disease.